Cost effectiveness in Canada of eptifibatide treatment for acute coronary syndrome patients using PURSUIT subgroup analysis.
Bibliographic record
Abstract
OBJECTIVE: To evaluate the cost effectiveness of eptifibatide, a new glycoprotein IIb/IIIa receptor inhibitor, for the treatment of acute coronary syndromes (ACS) in Canada. DESIGN: A model was created to analyze the cost effectiveness of eptifibatide using outcomes and resource utilization data from the Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial, an international, placebo controlled, randomized clinical study evaluating the efficacy of eptifibatide in treating ACS. Cost data were derived from Canadian sources. Clinical outcomes were derived from published survival analyses based on North American PURSUIT data. SETTING: The present analysis is representative of the Canadian health care setting. Data for resource use reflected actual resources used by patients in the Canadian arm of the PURSUIT study. PATIENTS: Patients included in the PURSUIT study were hospitalized for non-ST segment elevation ACS between November 1995 and January 1997. INTERVENTIONS: Eptifibatide or placebo treatment was randomly assigned in addition to standard treatment with acetylsalicylic acid and heparin. MAIN RESULTS: Per patient costs for hospitalization, medical procedures and medications associated with standard treatment plus placebo were 10,265 dollars compared with 10,691 dollars with eptifibatide, in 1995 Canadian dollars. Eptifibatide patients had lower rehospitalization rates in the six months following treatment. Discounting future health outcomes by 3%, the cost effectiveness of treating ACS patients with eptifibatide in Canada was estimated as 5,165 dollars per year of life gained. CONCLUSIONS: Considering both the cost of eptifibatide therapy over standard treatment and the health benefits associated with it, eptifibatide is a cost effective, economically attractive pharmacological option for the treatment of ACS patients in Canada.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.003 | 0.007 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.004 |
| Bibliometrics | 0.001 | 0.001 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.001 | 0.000 |
| Open science | 0.001 | 0.001 |
| Research integrity | 0.001 | 0.001 |
| Insufficient payload (model declined to judge) | 0.002 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".